CD341 cell selection minimizes graft-versus-host disease (GVHD) after haploidentical donor stem cell transplant but is associated with slow immune recovery and infections. We report a Phase I/II study of prophylactic donor lymphocyte infusion (DLI) followed by methotrexate (MTX) GVHD prophylaxis after CD34-selected haploidentical donor transplant. A prophylactic DLI was given between day 130 and 142. Rituximab was given with DLI for the last 10 patients. The goal of the study was to determine a DLI dose that would result in a CD41 cell count > 100/mL at Day 1120 in 66% of patients with 33% grade II-III, 17% grade III, and no grade IV acute GVHD by Day 1180. Thirty-five patients with malignant (n 5 25) or nonmalignant disease (n 5 10) were treated after CD34-selected haploidentical donor peripheral blood stem cell transplant. The DLI dose of 5 3 10 4 /kg met the CD4/GVHD goal with 67% of patients having CD41 cells > 100/mL and 11% grade II-IV acute GVHD. The cumulative incidence of chronic GVHD was 16%. Fatal viral and fungal infections occurred in 11%. The 2 year estimated overall survival was 69% and the relapse rate was 14% for patients in remission at transplant. There was no effect of NK alloreactivity on relapse. Nine of ten patients at the target DLI dose cohort of 5 3 10 4 /kg are alive with median follow-up of 18 mos (range 6-29). Delayed prophylactic DLI and MTX was associated with promising outcomes at the target DLI dose. This trial was registered at clinicaltrials.gov, # NCT01027702.
| I N TR ODU C TI ON
Hematopoietic stem cell transplants (SCT) can cure children with malignant and nonmalignant disorders. For the > 70% of patients lacking a human leukocyte antigen (HLA) -identical family member donor, alternative donors include unrelated donors, cord blood, and mismatched family members. 1 A significant complication of unrelated donor or cord blood transplant is severe (grade III-IV) acute GVHD, which occurs in 13-23% of patients. 2, 3 Mismatched family member donor transplant without T cell depletion or post-transplant cyclophosphamide is associated with a very high risk of severe acute GVHD. 4 Removal of T cells by CD341 cell selection from the graft can prevent severe GVHD while having reasonable rates of graft failure and leukemic relapse. [5] [6] [7] [8] [9] However, the low number of T cells given with the SCT results in delayed immune recovery and a high risk of morbidity and mortality due to infections. 6 We report a Phase I/II study of a novel approach to achieve early immune recovery with acceptable GVHD, and a goal of reducing fatal infections following CD341 cell-selected haploidentical donor peripheral blood stem cell (PBSC) transplantation in children. The study was performed as a companion study to a Phase II study of CD341 cellselected haploidentical donor PBSC transplantation for malignant and nonmalignant disease (Supporting Information Figure S1 ). Patients were treated with a DLI 30-42 days after SCT followed by MTX for GVHD prophylaxis. The DLI was delayed to avoid killing of T cells in the DLI by rabbit anti-thymocyte globulin (rATG) used in the conditioning regimen that may persist for a month after SCT. 10 Our hypothesis was that the use of GVHD prophylaxis with MTX would prevent GVHD from the DLI by killing T cells responding to alloantigens in the recipient while sparing a sufficient number of viralspecific T cells to provide some immunity and protection from infection. Methotrexate is an anti-proliferative chemotherapy drug that has been used for the prevention of GVHD for many years. 11 Preclinical data showed that trimetrexate (a folate antagonist similar to methotrexate) reduced alloreactive T cells and remaining lymphocytes were able to respond to cells from a third party and to candidal antigens.
The use of post-transplant cyclophosphamide is based on the same concept. 13 
| M E TH ODS

| Patient eligibility
Patients were eligible if they had been treated on the companion study using the CliniMACS® device for CD341 cell selection for haploidentical donor SCT (clinicaltrials.gov, #NCT00968864). Exclusion criteria included active GVHD, a history of acute GVHD > grade I prior to DLI, disease due to viral infection (asymptomatic viral reactivation was not an exclusion after the first two patients on the companion study), uncontrolled bacterial or fungal infection, Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disorder (PTLD), inadequate organ function (creatinine > 3x baseline, O2 sat < 95%, ALT > 5x upper limit of normal or bilirubin > 3 mg/dL), absolute neutrophil count < 500/mL, significant pleural or pericardial effusions or ascites, or persistent or increasing mixed chimerism requiring therapeutic DLI based on the companion study. The study was approved by Carolinas
HealthCare System Institutional Review Board. All recipients (parents or guardians for minors) signed IRB-approved consent forms in accordance with the Declaration of Helsinki. 
| Donor lymphocyte infusion
| GVHD prophylaxis
MTX 10 mg/m 2 IV was given 24 hours after the DLI started and then weekly starting 3 days after the DLI (3, 10, 17, etc) . MTX was initially given through Day 124 after DLI (total of 5 doses). The duration was then increased to 52 days by adding two weekly doses of 7.5 mg/m . The duration of MTX was extended during the study in an attempt to improve patient safety, achieve tolerance, and more closely resemble long course MTX GVHD prophylaxis following cases of late acute GVHD. 11 The dose of methotrexate was adjusted for elevated bilirubin > 3 mg/dL or creatinine > 2x the upper limit of normal and was held for serum ALT > 20X the upper limit of normal or significant effusions or ascites. It could also be held at investigator discretion for infections such as sepsis or persistent significant viral infections.
| Supportive care
Patients remained on post-transplant infection prophylaxis including anti-viral prophylaxis, pneumocystis prophylaxis, anti-fungal prophylaxis, and IVIG per the companion study. Patients were monitored by PCR testing for cytomegalovirus (CMV), Human Herpes virus-6 (HHV-6), EBV, and adenovirus and pre-emptive therapy was initiated when positive.
| NK alloreactivity
NK alloreactivity was determined based on donor and recipient HLA-B
and HLA-C typing, killer immunoglobulin-like receptor (KIR) genotyping to calculate B cell content using centromeric and telomeric B score, and KIR phenotyping by flow cytometry as previously described. 14, 15 Donor choice was based on NK alloreactivity when multiple donors were available for patients with malignant disease.
| Immune recovery assays
Immune recovery was tested at Day 120 and 6 and 12 months after size spectratyping was performed as described previously 16 
| Statistics
The primary study objective was to determine a target DLI dose at which the:
1. Probability of CD41 cells > 100/mL by Day 1120 is at least 66% and 2. Probability of grade II and III GVHD is at most 33%, probability of grade III GVHD is at most 17%, and no grade IV GVHD occurs
The immune recovery goal was based on CD31 cell > 100/mL correlating with protection from serious infection. 7 The GVHD goal was based on the GVHD incidence after cord blood transplantation. 20 Patients were evaluated for acute GVHD due to prophylactic DLI between the day of prophylactic DLI infusion and Day 1180 after transplant. Patients that had not had grade II-IV acute GVHD following prophylactic DLI but received therapeutic DLI (eg. for treatment of viral infection or relapse), chemotherapy, or a PBSC infusion prior to Day 1180 were considered not evaluable because these therapies may cause or prevent GVHD and affect the determination of this endpoint.
The study design consisted of two phases, a dose-escalation phase and a dose-confirmation phase. In the dose-escalation phase, an A 1 B design 21 for the dual objective (1) and (2) above was used with patients assigned in cohorts of 3. Additionally, to make decisions about dose assignment of new patients in the case when some patients were still followed for GVHD, we used the method for mitigating uncertainty in phase I trials. 22 There was no cohort without DLI because previous studies have demonstrated prolonged severe lymphopenia with CD341 cell-selected grafts. 6 The dose escalation plan was:
If a grade IV acute GVHD event was observed at any dose, no more patients were assigned to this or higher dose levels unless the methotrexate dosing was modified.
If none of the initial three patients at a dose level experienced grade II/III GVHD and < 2/3 had a CD41 count > 100 at Day 1120, the next three patients were assigned to the next higher dose level.
If 1 out of 3 patients had grade III GVHD or 1 -2 out of 3 patients had grade II GVHD and/or > 2/3 have a CD41 count > 100 at Day 1120, the dose was repeated for the next 3 patients. When the dose was repeated for the next 3 patients:
If < 2/6 patients had grade II/III GVHD and < 1/6 patients had grade III GVHD and < 4/6 patients had a CD41 count > 100 at Day 1120, the dose was increased for the next group of patients.
If < 2/6 patients had grade II/III GVHD and < 1/6 patients had grade III GVHD and > 4/6 patients had a CD41 count > 100 at Day 1120, this dose was selected for the dose confirmation phase.
If all 3 patients have grade II GVHD events or 2 patients had grade III GVHD, 3 more patients were assigned to the next lower dose level, unless there are already 6 patients at that dose level.
Because of the relatively long time for a patient to be evaluable:
While the initial 3 patients at a dose level were being followed, additional patients could be enrolled at the same dose level if none of the initial 3 have grade II/III GVHD within 30 days of DLI.
While patients in the second group of 3 at a dose level were being If the above criteria were not met, then the additional patients were enrolled at a previous, lower dose level.
When the patients being followed were at the initial dose (3 3 10 4 / kg), the additional patients were treated at this dose.
The dose-escalation phase was continued until the maximum dose of DLI was reached or until escalation was stopped for toxicity or efficacy.
After the dose-escalation phase and target dose identification, up to 10 more patients could be treated at the target dose in a dose confirma- Twenty-five patients were transplanted for malignant disease and ten for nonmalignant disease. The median recipient age was 11 years (range 0. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Eight patients on the companion CD341 cell selection study were not enrolled on this study because of parental refusal (n 5 2), decreasing donor chimerism (n 5 3), graft failure (n 5 1), viral reactivation prior to this being removed as an eligibility criterion (n 5 1), and PTLD (n 5 1). All but the parental refusal patients received therapeutic DLI or PBSC and cannot be used for comparison of immunological recovery. A summary of patient characteristics, treatment, and outcome is provided in Table 1 and   Supporting Information Table S1 . The median CD341 cell dose was Day 1180, thus meeting the GVHD target. One patient at this dose had chronic GVHD, which was extensive lichenoid skin changes (moderate by NIH GVHD severity scoring).
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The median time to CD41 cells > 100/mL was 122 days after SCT (range 55-342) and to > 200/mL was 153 days (range 55-452) for 29 patients who reached these endpoints. CD41 cell recovery by DLI cohort is shown in Table 3 . The median time to PHA response > 50% of normal was 6.4 months (range 3-38) and to normal was 7.5 months (range 3-38). Several patients were assigned a unique patient number (UPN) but did not proceed to transplant and are not included in the results. For follow-up, number of months without a 1 means that the patient died; relapse is noted if this occurred. Abbreviations: ALL, acute lymphoblastic leukemia; CR, complete remission; AML, acute myelogenous leukemia; SCT, stem cell transplant; HLH, hemophagocytic lymphohistiocytosis; MDS, myelodysplatic syndrome; JMML, juvenile myelomonocytic leukemia; MRD, minimal residual disease; APML, acute promyelocytic leukemia; SCID, severe combined immunodeficiency; CNS, central nervous system; VOD, veno-occlusive disease; PRES, posterior reversible encephalopathy syndrome; TCD, transcranial Doppler; MRI, magnetic resonance imaging; AVN, avascular necrosis; H/O, history of. * Prophylactic DLI dose.
The cumulative incidence of acute GVHD grade II-IV and grade III-IV by Day 1180 after SCT and prophylactic DLI was 21% and 4%, respectively. Five patients had grade II, one had grade III, and none had grade IV acute GVHD by Day 1180 and one patient, who previously had grade I, had grade II after day 1180. GVHD by DLI dose cohort is shown in Table 2 . Eight patients received therapeutic DLI subsequent to prophylactic DLI and prior to Day 1180 and 4 developed acute GVHD. The indication for therapeutic DLI was relapse (n 5 4), disseminated adenovirus (n 5 2), PTLD (n 5 1), and decreasing donor chimerism (n 5 1). The cumulative incidence of chronic GVHD after SCT and prophylactic DLI was 16% in 28 evaluable patients. Chronic GVHD was mild in two patients, moderate in one, and severe in two by NIH GVHD severity scoring.
| Infections
Infections that occurred were primarily viral. The recovery of CD41 cells > 100/mL correlated with the prevention of severe infections except for 3 patients who later received steroids (2 GVHD, 1 autoimmune hemolytic anemia [AIHA]) and 1 patient who developed PTLD coincident with CD41 cells > 100/mL. Viral reactivation of doublestranded DNA viruses and disease are summarized in Table 3 . Although CMV and HHV-6 reactivation was common, disease did not occur.
There was a fairly high incidence (4/35, 11%) of EBV-associated PTLD.
Early in the companion study, it was noted that PTLD was occurring in Both patients were on steroid therapy for GVHD. Two patients had a possible mold infection. 25 Death due to viral infections (adenovirus, HSV, and EBV) occurred in 11% of patients and no deaths were due to fungal infections.
| T and B cell subsets
T and B cell recovery is shown in Figure 1 . The median CD45RA 1 CCR71 (naïve) CD41 T cells/mL was 2 at Day 1120 after SCT in 18 patients, 12 at 6 months after SCT in 14 patients, and 262 at 12 months in 9 patients (Normal is > 100/mL per this lab).
| T cell diversity and T cell receptor excision circles (TREC)
TCR Vb chain CDR3 spectratyping was evaluated in 13 patients at the St. Jude laboratory. The median Vb complexity score was 0 at Day 1120 after SCT in 13 patients, increased rapidly to 114 at 6 months after SCT in 11 patients, and improved to normal range at 139 at 12 , and CD191 lymphocyte subsets were quantified in the Levine Children's Hospital Immunology Lab using the TetraCXP system (antibodies recognizing CD45, CD3, CD4, and CD8) and a FC500 flow cytometer (Beckman Coulter, Indianapolis, IN). For (A-C), all patients were tested and all results are shown except those after relapse. CD45RA and CCR7-expressing cells were quantified as previously described. 26 Results are shown for 32 patients who received prophylactic DLI and had a sample at Day 120 in (A-C) and for 21 of these patients who were tested for the subsets in (D-F) months in 6 patients. 16, 27 Vb scores are shown in Supporting Informa- The median number of TREC was 0 copies/mL at Day 1120 after SCT in 16 patients. The median number of TREC was 202 copies/mL at 6 months after SCT in 11 patients which is below the median of 3,000/mL reported in normal children and young adults from the same lab. 27 Four patients had a normal Vb score and normal TREC at 6 months. Two patients had a normal Vb score with very low TREC and 3 had a mildly low Vb score of 68-91 with very low TREC. The remaining two had a very low Vb score and TREC.
| Toxicity
The incidence and severity of toxicities were typical of SCT and T celldepletion except possibly for TMA which was seen at a higher frequency than anticipated. Table S2 .
| Transplant-related mortality and survival
Day 100 TRM was 0% and the cumulative incidence of TRM at 2 years was 25%. The 2 year OS was 63% for all patients and 69% if the 3 patients with active disease are excluded. The 2 year OS was 61% for patients with malignant disease in remission and 86% for patients with nonmalignant disease. The actuarial survivals are shown in Supporting
Information Figure S3 . The survival was 62% for 8 patients (7 with nonmalignant disease) receiving CD34-selected SCT without prophylactic DLI. Causes of death are summarized in Supporting Information Table S3 . of T cells in the PBSC graft, and conditioning regimen. 34 Murine models suggested that a delayed DLI separated from the transplant would prevent GVHD. 35 Early (e.g., 1 month after transplant) DLI without GVHD prophylaxis carries a significant risk of severe acute GVHD. 36, 37 Our hypothesis was that MTX prophylaxis would prevent GVHD and allow DLI to be given safely early after transplant. The duration of MTX was extended during the study because cases of late acute GVHD suggested a failure to achieve tolerance. Two early patients developed acute GVHD 6 weeks after ending MTX, after the end of the GVHD assessment period. As the duration of MTX was extended, so was the time point for evaluation of acute GVHD in order to detect late acute GVHD. Although the MTX duration was extended during the study in addition to the DLI dose escalation, the majority of patients (25 of 35) received the 80 day duration. Because this was a Phase I study, early cohorts were small and there was never any intention of formally comparing outcomes between cohorts. Rather, the goal of the study was to determine a dose at which the composite endpoint was achieved.
| D ISC USSION
At the prophylactic DLI dose of 5 3 10 4 CD31/kg, two of 10 patients developed disease due to double-stranded DNA viruses. One patient had a history of severe CNS HLH and had received 40 mg/kg of Thymoglobulin® and 0.6 mg/kg of alemtuzumab prior to transplant.
The other patient developed polymorphic PTLD. He was not treated with rituximab for EBV reactivation per protocol because he was starting to have T cell recovery at the time and it was thought that the T cells would prevent disease. He had a rapid increase of CD81 T cells in his blood and many CD41 and CD81 T cells in a node biopsy suggesting that he may have been starting to control the disease.
The relapse rate was low for patients in morphological remission despite the high risk study population. There was no impact of NK alloreactivity on relapse. It is possible that the prophylactic DLI provided an anti-leukemic effect that obscured the NK effect. This suggests that our approach may be helpful for situations without NK alloreactivity, which has been reported to be very important for preventing relapse in the setting of other studies of T cell depletion.
14,38
Following a comprehensive review of study data in September 2014, it was noted that a significant number of subjects began to have In summary, our approach of prophylactic DLI with MTX prophylaxis following CD341 cell-selected haploidentical donor SCT identified a DLI dose associated with early immune recovery in the majority of patients. The incidence of acute and chronic GVHD was low and no severe acute GVHD was seen with the final MTX duration. The relapse rate was low for patients in remission. The survival for patients treated at the target DLI dose is encouraging and warrants further study. 
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